Literature Review
Key Literature
Table of Contents
Annotative Bibliography
Annotative Bibliography
Etiology
Cardiovascular risk factors and venous thromboembolism: a meta-analysis.
Ageno W, Becattini C, et, al. Circulation. 2008 Jan 1;117(1):93-102. Epub 2007 Dec 17. PMID: 18086925
Venous thromboembolism in children.
Parasuraman S, Goldhaber SZ. Circulation. 2006 Jan 17;113(2):e12-6. PMID: 16418440
Venous Thromboembolism Guidebook Fifth Edition
Piazza, G and Goldhaber SZ.Crit Pathways in Cardio l2006;5: 211–227.
Acute Pulmonary Embolism: Part I: Epidemiology and Diagnosis
Piazza G and Goldhaber SZ. Circulation 2006; 114;28-32. PMID: 16831989 No abstract available.
Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial.
Cushman M, Glynn RJ, et, al. J Thromb Haemost. 2006 Oct;4(10):2199-203. Epub 2006 Jul 26. PMID: 16869933
Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial.
Ray JG, Kearon C, et, al. Ann Intern Med. 2007 Jun 5;146(11):761-7. Epub 2007 Apr 30. PMID: 17470822
Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors.
Tillie-Leblond I, Marquette CH, et, al. Ann Intern Med. 2006 Mar 21;144(6):390-6. PMID: 16549851
Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Freudenberger RS, Hellkamp AS, et, al. Circulation. 2007 May 22;115(20):2637-41. Epub 2007 May 7. PMID: 17485579
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.
Cohen AT, Agnelli G, Thromb Haemost. 2007 Oct;98(4):756-64. PMID: 17938798
No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.
Morris TA, Castrejon S, et, al. Chest. 2007 Oct;132(4):1131-9. Epub 2007 Jul 23. PMID: 17646239
So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not?
Warkentin TE, Greinacher A. Chest. 2007 Oct;132(4):1108-10. PMID: 17934108 No abstract available.
Venous thromboembolism in the outpatient setting.
Spencer FA, Lessard D, et, al. Arch Intern Med. 2007 Jul 23;167(14):1471-5. PMID: 17646600
Risk factors for venous thromboembolic events in cancer patients.
Kröger K, Weiland D, et, al. Ann Oncol. 2006 Feb;17(2):297-303. Epub 2005 Nov 9. PMID: 16282243
A Prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.
Goldhaber SZ, Tapson VF Am J Cardiol 2004;93:259-262. PMID: 14715365
Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.
Smeeth L, Cook C, Thomas S et al Lancet April 1 2006 367:1075-1079. PMID: 16581406
HIT (Heparin Induced Thrombocytopenia).
Arepally GM, Ortel T L. NEJM August 24, 2006, 355(8): 809-817. PMID: 16928996 No abstract available.
Heparin Induced Thrombocytopenia.
Baroletti SA and Goldhaber SZ Circulation 2006; 114: 355-6. PMID: 16923760 No abstract available.
How frequently is venous thromboembolism in heparin treated patients associated with HIT?
Levine RL, McCollum D, Hursting MJ Chest 2006;130;681-687. PMID: 16963663
Venous Thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.
Lepercq J, Conard J, Borel-Derlon A, et al. Br J Obstet Gynaecol 2001; 108:1134-1140. PMID: 11762651
Thrombosis during pregnancy and the postpartum period.
James AH, Tapson VF, Goldhaber SZ Am J Obs Gyn 2005;193:216-219. PMID: 16021082
Hormonal factors and the risk of recurrent venous thrombosis: The PREVENT Trial.
Cushman M, Glynn RJ, Goldhaber SZ J of Thromboses and Haemostasis 2006; 4:2199-203. PMID: 16869933
Back to top.
Prevention/Patient Safety
Anticoagulant prophylaxis in special populations with an indwelling epidural catheter or renal insufficiency.
Douketis JD, Rabbat C, et, al. J Crit Care. 2005 Dec;20(4):324-9. PMID: 16310603
Thromboprophylaxis in medical and surgical patients undergoing physical medicine and rehabilitation: consensus recommendations.
Ginzburg E, Banovac K, et, al. Am J Phys Med Rehabil. 2006 Feb;85(2):159-66. PMID: 16428908
D-dimer, factor VII coagulant activity, low-intensity warfarin and risk of recurrent venous thromboembolism.
Shrivastava S, Ridker PM, Glynn R, et al. J of Thrombosis and Haemostasis, 2006, 4:1208-1214. PMID: 16706961
Acute Pulmonary Embolism: Part II: Treatment and Prophylaxis.
Piazza G and Goldhaber SZ Circulation 2006; 114;42-47. PMID: 16847156 No abstract available.
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group.
[No authors listed]. Br J Surg. 1997 Aug;84(8):1099-103. PMID: 9278651
Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology.
Steffen LM, Folsom AR, et, al. Circulation. 2007 Jan 16;115(2):188-95. Epub 2006 Dec 18. PMID: 17179018
New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism.
Schulman S, Ogren M. Thromb Haemost. 2006 Sep;96(3):258-66. PMID: 16953265
Effectiveness of a guideline for venous thromboembolism prophylaxis in elderly post-acute care patients: a multicenter study with systematic ultrasonographic examination.
Sellier E, Labarere J, et, al. Arch Intern Med. 2006;166:2065-2071. PMID: 17060535
Prevention of Venous Thromboembolism
Goldhaber, SZ. Kardiovaskuläre Medizin 2006;9:102–108.
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study.
Glynn RJ, Ridker PM, et, al. Circulation. 2007 Sep 25;116(13):1497-503. Epub 2007 Sep 10. PMID: 17846285
Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists.
Goldhaber SZ. J Thromb Haemost 2007; 5: 1607–9. PMID: 17663732 No abstract available.
Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients.
Dentali F, Douketis JD, et, al. Ann Intern Med. 2007 Feb 20;146(4):278-88. PMID: 17310052
Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis.
King CS, Holley AB, et, al. Chest. 2007 Feb;131(2):507-16. PMID: 17296655
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.
Kahn SR, Panju A, et, al. Thromb Res. 2007;119(2):145-55. Epub 2006 Mar 3. PMID: 16516275
Hospitals' compliance with prophylaxis guidelines for venous thromboembolism.
Yu HT, Dylan ML, et, al. Am J Health Syst Pharm. 2007 Jan 1;64(1):69-76. PMID: 17189583
Thromboprophylaxis rates in US medical centers: success or failure?
Amin A, Stemkowski S, Lin J, Yang G. J Thromb Haemost 2007; 5: 1610–6. PMID: 17663733
Venous thromboembolism risk among hospitalized patients: magnitude of the risk is staggering.
Goldhaber SZ. Am J Hematol. 2007 Sep;82(9):775-6. PMID: 17626256
Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism.
Anderson FA Jr, Zayaruzny M, et, al. Am J Hematol. 2007 Sep;82(9):777-82. PMID: 17626254
A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism.
Mismetti P, Rivron-Guillot K, et, al. Chest. 2007 Jan;131(1):223-9. PMID: 17218580
Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry.
Falgá C, Capdevila JA, et, al. Thromb Haemost. 2007 Oct;98(4):771-6. PMID: 17938800
Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients.
Francis, CW. N Engl J Med. 2007 Apr 5;356(14):1438-44. PMID: 17409325 No abstract available.
Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent.
Piazza G, Seddighzadeh A, Goldhaber SZ. Chest. 2007 Aug;132(2):554-61. Epub 2007 Jun 15. PMID: 17573518
Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.
Tapson VF, Decousus H, et, al. Chest. 2007 Sep;132(3):936-45. Epub 2007 Jun 15. PMID: 17573514
Inferior vena cava filters in venous thromboembolism.
Weichman K, Ansell JE. Prog Cardiovasc Dis. 2006 Sep-Oct;49(2):98-105. PMID: 17046435
Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
Wein L, Wein S, et, al. Arch Intern Med. 2007 Jul 23;167(14):1476-86. PMID: 17646601
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Geerts WH, Pineo GF, et, al. Chest. 2004 Sep;126(3 Suppl):338S-400S. PMID: 15383478
Prevention of Deep Vein Thrombosis & Pulmonary Embolism.
Goldhaber SZ and Fanikos J. Cardiology patient pages. Prevention of deep vein thrombosis and pulmonary embolism. Circulation. 2004 Oct 19;110(16):e445-7. PMID: 15492324 No abstract available.
Seminar: Pulmonary Embolism. Goldhaber, SZ. Lancet 363:1296-1305 (April, 2004)
Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Bates SM, Greer AI, Hirsh J et al. Chest 2004;126(3):627s-644s. PMID: 15383488
Thromboprophylaxis during pregnancy, labour, and after vaginal delivery.
Royal College of Obstetricians and Gynecologists.
Available at www.rcog.org.uk. Accessed 16 August 2005
Thromboprophylaxis in Medical and Surgical Patients Undergoing Physical Medicine and Rehabilitation. Consensus Recommendations.
Ginzburg E, Banovac K Epstein B et al. Am J Phys Med Rehab. Feb 2006 85(2): 159 – 166. PMID: 16428908
Effectiveness of a Guideline for VTE Prophylaxis in Elderly Post-Acute Care Patients:
A Multi-Center Study with Systematic Ultrasonographic Examination.
Sellier, E, Labarere J, Bosson, J et al.Arch Intern Med 2006;166:2065-2071. PMID: 17060535
Back to top.
Randomized Control Trials
The Prince Study: Prevention in Cardiopulmonary Diseases with Enoxaparin.
The Prince Study: Prevention in Cardiopulmonary Diseases with Enoxaparin, Kleber, F.X. et al. Am Heart J 2003; 145:614-21.
The MEDENOX Trial: A Comparison of Enoxaparin with Placebo for the prevention of Venous Thromboembolism in Acutely ill Medical Patients.
Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 Sep 9;341(11):793-800. PMID: 10477777
The PRIME Study: The Venous Thrombotic Risk in Non-Surgical Patients: Epidemiological Data and Efficacy/Safety Profile of LMWH (Enoxaparin).
The PRIME Study: The Venous Thrombotic Risk in Non-Surgical Patients: Epidemiological Data and Efficacy/Safety Profile of LMWH (Enoxaparin), Lechler, E. et al. Haemostasis 1996; 26(suppl 2): 49-56.
The Prevent Trial: Randomized, Placebo-Controlled trial of Dalteparian for Prevention of Venous Thromboembolism in Acutely ill medical Patients.
Leizorovicz Alain, Cohen Alexander, Turpie Alexander, Gustav-Olsson Carl, Vaitkus Paul and Goldhauber Samuel. Circulation. 2004 Aug 17;110(7):874-9. Epub 2004 Aug 02. PMID: 10477777
The ARTEMIS Trial: Arixtra for ThromboEmbolism Prevention in a Medical Indications Study.
The ARTEMIS Trial: Arixtra for ThromboEmbolism Prevention in a Medical Indications Study. Cohen, A. et al. J Thromb Haemost 2003;1(suppl 1):P2046.
Heparin-Induced Thombocytopenia Diagnosis & Management
Warkentin TE, Heparin-induced thrombocytopenia: diagnosis and management. Circulation. 2004 Nov 2;110(18):e454-8. PMID: 15520327 No abstract available.
Back to top.
Therapeutics
Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism.
Shetty R, Seddighzadeh A, et, al. Thromb Haemost. 2007;98(6):1384-1386. PMID: 18064344 No abstract available.
Percutaneous mechanical thrombectomy for massive pulmonary embolism: improve safety and efficacy by sharing information.
Goldhababer, SZ. Catheter Cardiovasc Interv. 2007 Nov 15;70(6):807-8. PMID: 18022903
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
Douketis JD, Gu CS, et, al. Ann Intern Med. 2007 Dec 4;147(11):766-74. PMID: 18056660
Venous thromboembolism in children.
Parasuraman S, Goldhaber SZ. Circulation. 2006 Jan 17;113(2):e12-6. PMID: 16418440
Venous Thromboembolism Guidebook Fifth Edition
Piazza, G and Goldhaber SZ.Crit Pathways in Cardiol 2006;5: 211–227.
Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
Veeger NJ, Piersma-Wichers M, et, al. Br J Haematol. 2005 Feb;128(4):513-9. PMID: 15686461
HIT (Heparin Induced Thrombocytopenia).
Arepally GM, Ortel T L. NEJM August 24, 2006, 355(8): 809-817. PMID: 16928996 No abstract available.
Trials that matter: can patients with venous thromboembolism be treated with fixed-dose subcutaneous unfractionated heparin?
Goldhaber SZ, Berkwits M. Ann Intern Med. 2006;145:929-931. PMID: 17179061 No abstract available.
Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population.
Garcia D, Regan S, et, al. Chest. 2005 Jun;127(6):2049-56. PMID: 15947319
Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a meta-analysis.
Shorr AF, Jackson WL, et, al. Chest. 2008 Jan;133(1):149-55. Epub 2007 Oct 9. PMID: 17925410
Dalteparin Reduced Recurrent Venous Thromboembolism More then Oral Anticoagulation in Patients with Cancer.
Dalteparin reduced recurrent venous thromboembolism more than oral anticoagulation in patients with cancer. ACP J Club. 2004 Jan-Feb;140(1):10. PMID: 14711281 No abstract available.
Fondaparinux was not inferior to unfractioned heparin for symptomatic pulmonary embolism.
Baller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-702. PMID: 14585937
High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in the antiphospholipid antibody syndrome.
Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-8. PMID: 13679527
Comparison of a single end point to determine optimal initial warfarin dosing (5 versus 10 mg) for venous thromboembolism.
Quiroz R, Gerhard-Herman M, Kosowsky JM et al Am J Card 2006; 98:535-7. PMID: 16893712
Acute Pulmonary Embolism: Part II: Treatment and Prophylaxis.
Piazza G and Goldhaber SZ Circulation 2006; 114;42-47. PMID: 16847156 No abstract available.
Thrombolytic therapy of pulmonary embolism: a meta-analysis.
Thabut G, Thabut D, Myers RP et al. J Am Coll Cardiol 2002; 40:1660-1667. PMID: 12427420
Massive pulmonary embolism.
Kucher N, Rossi E, De Rosa M et al. Circulation 2006; 113:577-582. PMID: 16432055
Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism.
Konstantinides S, Geibel A, Heusel G et al. NEJM 2002;347:1143-1150. PMID: 12374874
A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism.
Simonneau G, Sors H, Charbonnier B et al. NEJM 1997; 337:663-9. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. PMID: 9278462
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
Buller HR, Davidson BL, Decousus H et al. NEJM 2003; 349:1695-1702. PMID: 14585937
Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism.
Kucher N, Quiroz R, McKean S et al. Vascular Medicine 2005; 10:1-6. PMID: 16444853
Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Mismetti P, Quenet S, Levine M et al Chest October 2005 128(4) 22032210. PMID: 16236875
Low-molecular-weight heparin compared with intravenous unfractionated heparin for the treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
Quinlan DJ, McQuillan A, Eikelboom JW. Ann Intern Med 2004; 140: 175-183. PMID: 14757615
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Levine M, Gent M, Hirsh J et al. NEJM March 14, 1996 334:677-681. PMID: 8594425
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Breddin HK, Hach-Wunderle V, Nakow RN et al. NEJM March 1, 2001 344(9):62631. PMID: 11228276
New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism.
Schulman Sam and Ogren Mats Thromb Haemost 2006; 96:258-66. PMID: 16953265
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM, Goldhaber SZ, Danielson E et al NEJM 2003; 348:1425-1434. PMID: 12601075
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
Kearon C, Ginsberg JS, Kovacs MJ et al. NEJM 2003: 349;631-639. PMID: 12917299
Extended oral anticoagulant therapy after a first episode of pulmonary embolism.
Agnelli G, Prandoni P, Becattini C, et al. Ann Intern Med 2003; 139:19-25. PMID: 12834314
The CLOT Trial: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AYY, Levine MN, Baker RI et al. NEJM July 10, 2003; 349;146-153. PMID: 12853587
Meyer G et al. Arch Intern Med 2002; 162:1729-1735.
Long-term management of patients after venous thromboembolism.
Kearon C Circulation 2004 Aug 31: 110(9 Suppl 1):I10-8. PMID: 15339876
Prevention of recurrent idiopathic venous thromboembolism. (i.e. duration of treatment)
Goldhaber GZ Circulation 2004 Dec 14:110(24 Suppl 1):IV20-4. PMID: 15598644
Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD, Pineo GF. Semin Thromb Hemost 2004 Feb;30 Suppl 1:11-23. PMID: 15085462
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Becker RC, Spencer FA, Gibson, SM et al. Am Heart J 2002;143:753-759. PMID: 12040334
Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW, Lee JJ Am Heart J 2004; 148:582-589. PMID: 15459586
Back to top.
Diagnosis
Venous thromboembolism in children.
Parasuraman S, Goldhaber SZ. Circulation. 2006 Jan 17;113(2):e12-6. PMID: 16418440
Venous Thromboembolism Guidebook Fifth Edition
Piazza, G and Goldhaber SZ.Crit Pathways in Cardiol 2006;5: 211–227.
Diagnosing pulmonary embolism with improved certainty and simplicity.
Hull RD. JAMA. 2006 Jan 11;295(2):213-5. PMID: 16403934 No abstract available.
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography.
van Belle A, Büller HR, et, al. JAMA. 2006 Jan 11;295(2):172-9. PMID: 16403929
HIT (Heparin Induced Thrombocytopenia).
Arepally GM, Ortel T L. NEJM August 24, 2006, 355(8): 809-817. PMID: 16928996 No abstract available.
Heparin-induced thrombocytopenia.
Baroletti SA, Goldhaber SZ. Circulation. 2006 Aug 22;114(8):e355-6. PMID: 16923760 No abstract available.
D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review.
Stein PD, Hull RD, et, al. Ann Intern Med. 2004 Apr 20;140(8):589-602. PMID: 15096330
Time-resolved MR angiography: a primary screening examination of patients with suspected pulmonary embolism and contraindications to administration of iodinated contrast material.
Ersoy H, Goldhaber SZ, et, al. AJR Am J Roentgenol. 2007 May;188(5):1246-54. PMID: 17449767
Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.
Wells PS, Anderson DR, Rodger M, et al. D-dimer testing reduced the need for ultrasonographic imaging in outpatients with suspected deep venous thrombosis. N Engl J Med. 2003;349:1227-35. PMID: 14507948
D-dimer, factor VII coagulant activity, low-intensity warfarin and risk of recurrent venous thromboembolism.
Shrivastava S, Ridker PM, Glynn R, et al. J of Thrombosis and Haemostasis, 2006, 4:1208-1214. PMID: 16706961
Acute Pulmonary Embolism: Part I: Epidemiology and Diagnosis
Piazza G and Goldhaber SZ Circulation 2006; 114;28-32. PMID: 16831989 No abstract available.
Back to top.
Clinical Prediction Guides
Venous Thromboembolism Guidebook, fourth addition.
Gelfand Eli, Piazza Gregory, Goldhaber Samuel. Venous Thromboembolism Guidebook, fourth addition. 2003;2:247-265.
Antihrombolic Therapy for Venous Thromboelbolic Disease.
Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):688S-696S. Review. PMID: 15383490
Back to top.
Prognosis
Validation of a model to predict adverse outcomes in patients with pulmonary embolism.
Aujesky D, Roy PM, et, al. Eur Heart J. 2006 Feb;27(4):476-81. Epub 2005 Oct 5. PMID: 16207738
The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study.
Nijkeuter M, Söhne M, et, al. Chest. 2007 Feb;131(2):517-23. PMID: 17296656
Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).
Goldhaber SZ, Visani L, De Rosa M. Lancet 1999; 353:1386-1389. PMID: 10227218
Right Ventricular Enlargement on Chest Computed Tomography – Prognostic Role in Acute Pulmonary Embolism.
Quiroz Rene, Kucher Nils, Shoeph Joseph, Kipfmueller Florian, Solomon Scott, Costello Phillip, and Goldhaber Samuel. Right Ventricular Enlargement on Chest Computed Tomography: Prognostic Role in Acute Pulmonary Embolism. 2004;109:2401-2404. PMID: 15148278
Men had greater risk for recurrent venous thromboembolism than women.
Men had greater risk for recurrent venous thromboembolism than women. ACP J Club. 2004 Nov-Dec;141(3):78. PMID: 15518462 No abstract available.
Right Ventricular Enlargement on Chest Computed Tomography – A Prediction of Early Death in Acute Pulmonary Embolism.
Shoeph Joseph, Kucher Nils, Kipfmueller Florian, Quiroz Rene, Costello Phillip, and Goldhaber Samuel. Right Ventricular Enlargement on Chest Computed Tomography: A Predictor of Early Death in Acute Pulmonary Embolism. 2004;110:3276-3280. PMID: 15533868
Back to top.
Patient Education
Cardiology Patient Page: Prevention of deep vein thrombosis and pulmonary embolism
Goldhaber Samuel and Fanikos John. Circulation. 2004 Oct 19;110(16):e445-7. PMID: 15492324 No abstract available.
Back to top.
Economics
Cost Implications of Using Unfractionated Heparin or Enoxaparin in Medical Patients
at Risk for Venous Thromboembolic Events.
Weinberg, R, Lichtig, L, et, al. P&T®. June 2006;Vol. 31 No. 6.
Measuring Clinical Effectiveness Using Common Hospital Data.
Lichtig, L, Weinberg, R, et, al. P&T®. May 2004; Vol. 29 No. 5.
Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for the Treatment of Acute Deep Venous Thrombosis. A Cost-Effectiveness Analysis.
Gould M, Dembitzer AD, Sanders GD et al. Annals of Int Med May 18, 1999 130(10): 789-809. PMID: 10366368
Management of Acute Proximal Deep Vein Thrombosis: Pharmacoeconomic Evaluation of Outpatient Treatment with Enoxaparin vs Inpatient Treatment with Unfractionated Heparin.
Spyropoulos AC, Hurley JS, Ciesla GN et al. Chest 2002;122:108-114. PMID: 12114345
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients
McGarry LJ, Thompson D, Weinstein MC et al. The American Journal of Managed Care September 2004; 10:632-642. PMID: 15515996
Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism.
Avorn J, Winkelmayer WC. Circulation. 2004 Dec 14;110(24 Suppl 1):IV25-32. PMID: 15598645
Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.
Ollendorf DA, Vera-Llonch M, Oster G. J Health Sys Pharm 2002; 59:1750-1754. PMID: 12298113
Back to top.
Surgical VTE Prophylaxis
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.
Hull RD, Pineo GF, et, al. Arch Intern Med. 2000 Jul 24;160(14):2199-207. PMID: 10904464
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
Hull RD, Pineo GF, et, al. Arch Intern Med. 2000 Jul 24;160(14):2208-15. PMID: 10904465
Antithrombotic therapy in gynecologic surgery and gynecologic oncology.
von Tempelhoff GF, Heilmann L. Hematol Oncol Clin North Am. 2000 Oct;14(5):1151-69, ix. PMID: 11005039
Prevention of pulmonary embolism in general surgery patients.
Zurawska U, Parasuraman S, et, al. Circulation. 2007 Mar 6;115(9):e302-7. PMID: 17339555
Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review.
Einstein MH, Pritts EA, Hartenbach EM. Gynecol Oncol. 2007 Jun;105(3):813-9. Epub 2007 Apr 20. PMID: 17449089
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD, Eriksson BI, et, al. Thromb Haemost. 2007 Jun;97(6):931-7. PMID: 17549294
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG, Bauer KA, et, al. Arch Intern Med. 2002 Sep 9;162(16):1833-40. PMID: 12196081
Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis.
Bergqvist D. J Surg Oncol. 2007 Feb 1;95(2):167-74. PMID: 17262765
Venous thromboembolism in patients undergoing surgery: Low rates of prophylaxis and high rates of filter insertion.
Seddighzadeh, A, Zurawska, U, et al. Thromb Haemost 2007; 98: 1220–1225. PMID: 18064317
Venous Thromboembolism in the outpatient setting.
Spencer FA, Lessard D, Emergy C, Reed G, Goldberg, RJ. Arch Intern Med 2007; 167:1471-1475. PMID: 17646600
...37% of all outpatient VTE are related to hospitalization and 5% to outpatient surgery within prior 3 months.
...2/3rd of these cased within prior 1 month.
...of those hosp that subsequently dev VTE, only 43% had received prophylaxis during hospitalization implication inpt VTE prophylaxis can reduce community-based BTE rate for up to 3 months following hosp or outpt surger
Extended-duration VTE prophylaxis in acutely ill med pts with related reduced mobility. The EXCLAIM study.
Hull, RD, Schellong,SM, Tapson VT et al. 2007 Congress of the International Society of Thrombosis and Hemostasis; July 7-13, 2007. Geneva Switzerland. Late breaking clinical trials, abstract 0-S-001.
Extended-duration thromboprophylaxis in acutely ill medical patients with reduced mobility: Methodology for the EXCLAIM study.
Hull, RD, Schellong SM, Tapson, VT et al. J Thromb Thrombolysis 2006; 22: 31-8. PMID: 16786230
Extended prophylaxis RCT for additional 28 days. 44% reduction in VTE. At 90 days after enrollment, the VTE rates for extended prophylaxis were 3% and 5.2% respectively (p = 0.0015)
A large-scale, global observational study of VTE risk and prophylaxis in the acute hospital care setting: the ENDORSE study.
Cohen, AT, Tapson, VF, Bergman JF et al. 2007 Congress of the International Society on Thrombosis and Hemostasis. July 6-12, 2007. Geneva Switzerland. Abstract 1STH 2007 0-S-002.
...highlighting underutilization of prophylaxis in 32 countries
Thromboprophylaxis rates in US medical centers: success or failure?
Amin A, Stemkowski S, Lin J, Yang G J. Thromb Haemost 2007, 5: 1610-1616. 96,104. PMID: 17663733
discharges reviewed from 277 US medical centers. Overall prophylaxis rate 62% but guideline-appropriate prophylaxis rate only 34%
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.
Agnelli G, Piovella F, Buoncristiani P, et al. N Engl J Med 1998;339:80-85. PMID: 9654538
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.
Agnelli G, Bolis G, Capussotti L, et al. Ann Surg 2006;243:89-95. PMID: 16371741
American Society of Anesthesiologists Physical Classification System.
Available at: www.asahq.org . Accessed May 2006.
A population- based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study.
Anderson FA, Wheeler HB, Goldberg RJ, et al. Arch Intern Med 1991;151:933-938. PMID: 2025141
Imagerie des complications mécaniques des filtres caves inférieurs [Imaging mechanical complications of inferior vena cava filters].
Arrive L, Rotenberg L, Monnier-Cholley L, et al. J de Radiology 2001;82:231-235. PMID: 11287853
The current challenge of venous thromboembolism (VTE) in the hospitalized patient. Part II: Treatment and prevention of DVT and PE - evolving risk-stratification and prophylaxis strategies for hospital-based medicine.
Bosker G, Poponick J, Emerman CL, et al. Available at: www.thrombosis-consult.com . Accessed October 28, 2003.
Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients.
Cerrato D, Ariano C, Fiacchino F. J Neurosurg 1978;49:378-381. PMID: 681999
Diabetes in Control. U.S. Diabetes Population Grows 86 Percent Over Last Decade.
Available at: www.diabetesincontrol.com. Accessed March 9, 2006.
Deep venous thrombosis after total joint arthroplasty: the role of compression ultrasonography and the importance of the experience of the technician.
Garino JP, Lotke PA, Kitziger KJ, et al. J Bone Joint Surg Am 1996;78:1359-1365. PMID: 8816651
A prospective study of venous thromboembolism after major trauma.
Geerts WH, Code KI, Jay RM, et al. N Engl J Med 1994;331:1601-1606. PMID: 7969340
A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.
Geerts WH, Jay RM, Code KI, et al. N Engl J Med 1996;335:701-707. PMID: 8703169
Prevention of venous thromboembolism.
Geerts WH, Heit JA, Clagett GP, et al. Chest 2001;119(1, suppl):132S-175S. PMID: 11157647 No abstract available.
Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Geerts WH, Pineo GF, Heit JA, et al. Chest 2004;126;338S-400S. PMID: 15383478
Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture.
Gent M, Hirsh J, Ginsberg JS, et al. Circulation 1996;93:80-84. PMID: 8616946
A prospective study of risk factors for pulmonary embolism in women.
Goldhaber SZ, Grodstein F, Stampfer MJ, et al. JAMA 1997 Jun 25;277(24):1933. PMID: 9039882
Pulmonary embolism after coronary artery bypass grafting.
Goldhaber SZ, Schoepf UJ. Circulation 2004;109;2712-2715. PMID: 15184296 No abstract available.
A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.
Goldhaber, SZ, Tapson VF; for the DVT FREE Steering Committee. Am J Cardiol 2004a;93:259-262. PMID: 14715365
Venous thromboembolism: an ounce of prevention (editorial).
Goldhaber SZ. Mayo Clin Proc 2005;80:725-726 . Available at: Mayo Clinic Proceedings - Medical journal specializing in Internal Medicine published by Mayo Foundation for Medical Education and Research (www.mayoclinicproceedings.com/ ). Accessed December 3, 2005.
RD heparin (ardeparin sodium) vs aspirin to prevent deep venous thrombosis after hip or knee replacement surgery (abstract)
Graor RA, Stewart JH, Lotke PA, et al. Chest 1992; 102:118S.
When should prophylactic anticoagulation begin after hip fracture?
Grant PJ and Jaffer 1-minute consult: Q: Cleveland Clinic Journal of Medicine, 2006, 73(9):785-792. PMID: 16970132 No abstract available.
Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.
Hansson P-O, Sorbo J, Eriksson H. Arch Intern Med 2000;160(6):769-774. PMID: 10737276
Ardeparin Arthroplasty Study Group. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study.
Heit JA, Berkowitz SD, Bona R, et al; Thromb Haemost 1997;77:32-38. PMID: 9031445
Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study.
Heit JA, Silverstein MD, Mohr DN, et al. Arch Intern Med 1999;159:445-453. PMID: 10074952
The thromboembolic risk in surgery.
Hoffmann R. Hepatogastroenterol 1991;38:272-278. PMID: 1937369
Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis.
Ibrahim EH, Iregui M, Prentice D, et al. Crit Care Med 2002;30:771-774. PMID: 11940743
| 
